FDA Pulls Heartburn Drug Zantac From Market

Title: FDA Pulls Heartburn Drug Zantac From MarketCategory: Health NewsCreated: 4/1/2020 12:00:00 AMLast Editorial Review: 4/2/2020 12:00:00 AM
Source: MedicineNet Digestion General - Category: Nutrition Source Type: news

Related Links:

AbstractLaryngopharyngeal Reflux Disease (LPRD) is form of extra-oesophageal reflux due to the backflow of gastric contents into the upper aero digestive tract leading to throat symptoms. World over, the prevalence rate of LPRD, ranges from 5 to 30%. The aim of this study was to find the prevalence rate of LPRD in Indian population. This was an observational study whereby the RSI questionnaire was circulated amongst the population and records collected. All subjects who had RSI score more than 13 were considered to be suffering from LPRD. 2300 responses were collected from almost all strata of population. Out of 2300 peopl...
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - Category: ENT & OMF Source Type: research
While most people are familiar with the hallmark symptoms of COVID-19 by now—cough, fever, muscle aches, headaches and difficulty breathing—a new crop of medical conditions are emerging from the more than 4 million confirmed cases of the disease around the world. These include skin rashes, diarrhea, kidney abnormalities and potentially life-threatening blood clots. It’s not unusual for viruses to directly infect and affect different tissues and organs in the body, but it is a bit unusual for a primarily respiratory virus like SARS-CoV-2, which is responsible for COVID-19, to have such a wide-ranging reach...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
Patients who took a common heartburn medicine while hospitalized for Covid-19 were more than twice as likely to survive the infection, according to a paper posted Friday on a pre-publication website. But it's unclear whether the patients fared better because of the famotidine or if it was a coincidence.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
The ongoing Class III recall is on account of "Discolouration" and because the product contains brown pellets, USFDA said. As per the US health regulator, a class III recall is initiated in a situation "in which use of or exposure to a violative product is not likely to cause adverse health consequences".
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
AbstractBackgroundA proportion of patients with gastroesophageal reflux disease (GERD) do not respond to proton pump inhibitor (PPI) therapy.Aim of the studyTo determine the  findings on high-resolution esophageal manometry (HREM) and 24-h pH recording in patients with typical GERD symptoms, refractory to PPI treatment.MethodsRetrospective analysis of prospectively maintained database of patients referred for HREM and 24-h pH recording was done. We selected patients who were referred for evaluation of refractory GERD symptoms despite>  8 weeks of at least once-daily PPI treatment. Details noted were dem...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
(Karolinska Institutet) Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia. Their results are published in the journal Alzheimer's&Dementia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
DR MARTIN SCURR: Any persistent problem can be terribly frustrating but it is not the Barrett's oesophagus (pictured) that is causing your symptoms.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
The search for existing drugs that may help treat coronavirus infections now has researchers testing the heartburn drug Pepcid, among others.
Source: L.A. Times - Health - Category: Consumer Health News Authors: Source Type: news
AbstractThe research aims to examine the effects of fructooligosaccharide (FOS) concentrations on the physicochemical properties of formulated sports drinks (FSDs) and the consumption of FSDs on the athletic gastrointestinal (GI) tolerance during intermittent high-intensity exercise. Three FSDs were developed from the diluted sugarcane juice (6.6% sugar content) with the addition of 2% calamansi juice, by varying FOS concentrations (0%, 1%, and 2% w/v). Thirty trained athletes performed four separate trials (1  week recovery period) using an exercise protocol consisting of sprint, lateral hopping, and sprint plus vert...
Source: Sport Sciences for Health - Category: Sports Medicine Source Type: research
When Dr. Kevin Tracey of Northwell Health's Feinstein Institutes for Medical Research got a call from a colleague who had been in Wuhan, China, seeing patients with COVID-19, the disease caused by the novel coronavirus, in January, his curiosity was piqued.Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
More News: Heartburn | Nutrition